Nexium Control

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
20-03-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
20-03-2024

Viambatanisho vya kazi:

esomeprazole

Inapatikana kutoka:

GlaxoSmithKline Dungarvan Limited

ATC kanuni:

A02BC05

INN (Jina la Kimataifa):

esomeprazole

Kundi la matibabu:

Proton pump inhibitors

Eneo la matibabu:

Gastroesophageal Reflux

Matibabu dalili:

Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.

Bidhaa muhtasari:

Revision: 17

Idhini hali ya:

Authorised

Idhini ya tarehe:

2013-08-26

Taarifa za kipeperushi

                                40
B. PACKAGE LEAFLET
41
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEXIUM CONTROL_ _20 MG GASTRO-RESISTANT TABLETS
esomeprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your pharmacist has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse after 14 days
WHAT IS IN THIS LEAFLET
1.
What Nexium Control is and what it is used for
2.
What you need to know before you take Nexium Control
3.
How to take Nexium Control
4.
Possible side effects
5.
How to store Nexium Control
6.
Contents of the pack and other information
- Further helpful information
1.
WHAT NEXIUM CONTROL_ _IS AND WHAT IT IS USED FOR
Nexium Control
_ _
contains the active substance esomeprazole. It belongs to a group of
medicines called
‘proton pump inhibitors’. They work by reducing the amount of acid
that your stomach produces.
This medicine is used in adults for the short-term treatment of reflux
symptoms (for example,
heartburn and acid regurgitation).
Reflux is the backflow of acid from the stomach into the gullet
(“foodpipe”) which may become
inflamed and painful. This may cause you symptoms such as a painful
sensation in the chest rising up
to your throat (heartburn) and a sour taste in the mouth (acid
regurgitation).
Nexium Control is not meant to bring immediate relief. You may need to
take the tablets for 2-3 days
in a row before you feel better. You must talk to a doctor if you do
not feel better or if you feel worse
after 14 days.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE NEXIUM CONTROL_ _
_ _
DO NOT TAKE NEXIUM CONTROL_ _
-
If you are allergic to esomeprazole or any of the other ingredients of
th
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Nexium Control
_ _
20 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium
trihydrate)
Excipient(s) with known effect
Each gastro-resistant tablet contains 28 mg sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet.
A light pink, oblong, biconvex, film-coated, gastro-resistant tablet
of 14 mm x 7 mm engraved with
‘20 mG’ on one side and ‘A/EH’ on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Nexium Control is indicated for the short-term treatment of reflux
symptoms (e.g. heartburn and acid
regurgitation) in adults.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
The recommended dose is 20 mg esomeprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to
achieve improvement of
symptoms. The duration of treatment is up to 2 weeks. Once complete
relief of symptoms has
occurred, treatment should be discontinued.
If no symptom relief is obtained within 2 weeks of continuous
treatment, the patient should be
instructed to consult a doctor.
_Special populations _
_Patients with renal impairment _
Dose adjustment is not required in patients with impaired renal
function. Due to limited experience in
patients with severe renal insufficiency, such patients should be
treated with caution (see section 5.2).
_Patients with hepatic impairment _
Dose adjustment is not required in patients with mild to moderate
liver impairment. However, patients
with severe liver impairment should be advised by a doctor before
taking Nexium Control (see
sections 4.4 and 5.2).
_Elderly patients (≥65 years old) _
Dose adjustment is not required in elderly patients.
3
_Paediatric population _
There is no relevant use of Nexium Control in the paediatric
population below 18 years of age for the
indication of “short-term treatment of reflux sympto
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kireno 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 20-09-2013
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 20-03-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 20-03-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 20-09-2013

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati